Amneal Launches Releuko (biosimilar, filgrastim) for the Treatment of Neutropenia
Shots:
- The company reported the commercial availability of Releuko, a biosimilar referencing Neupogen for neutropenia. Releuko was being developed in collaboration with Kashiv Biosciences
- Releuko was approved in the US in Mar 2022 & showed that the biosimilar & reference products were highly similar with no clinical differences & are available in single-dose vials & prefilled syringes containing 300/480mcg of filgrastim-ayow in a preservative-free solution
- The product is indicated to reduce the incidence of inf.; duration of neutropenia & neutropenia-related clinical sequelae for non-myeloid malignancies; time to neutrophil recovery & duration of fever for AML; incidence & duration of sequelae of sev. neutropenia for congenital neutropenia‚ CyN‚ or IN
Ref: Amneal | Image: Amneal
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
